VTRS
Viatris Inc
NASDAQ · Healthcare · Drug Manufacturers - Specialty & Generic · US
$16.95
−1.05%Next report
Analyst consensus
- Next report date
- Nov 5, 2026
- EPS estimate
- $0.66
- Revenue estimate
- $3.8B
Latest reported
- Last report date
- Aug 6, 2026
- EPS actual
- $0.69
- EPS estimate
- $0.60
- Revenue actual
- $3.8B
- Revenue estimate
- $3.7B
Track record
Trailing twelve quarters
- EPS beats (12Q)
- 7
- EPS misses (12Q)
- 4
- EPS in line (12Q)
- 1
- Avg surprise (4Q)
- -30.2%
- Revenue beats (12Q)
- 5
Analyst ratings
Sell-side consensus
- Consensus
- Buy
- Price target
- $18
- PT range
- $13 – $20
- Analysts
- 3
2 Buy1 Hold0 Sell
Reported history
| Report date | EPS estimate | EPS actual | Surprise | Revenue actual |
|---|---|---|---|---|
| Aug 6, 2026 | $0.60 | $0.69 | Beat 14.81% | $3.8B |
| May 7, 2026 | $0.52 | $0.59 | Beat 13.46% | $3.5B |
| Feb 26, 2026 | $0.52 | -$0.30 | Miss -156.85% | $3.7B |
| Nov 6, 2025 | $0.62 | $0.67 | Beat 7.89% | $3.8B |
| Aug 7, 2025 | $0.56 | $0.62 | Beat 11.51% | $3.6B |
| May 8, 2025 | $0.49 | $0.50 | Beat 1.65% | $3.3B |
| Feb 27, 2025 | $0.61 | $0.54 | Miss -11.48% | $3.5B |
| Nov 7, 2024 | $0.68 | $0.75 | Beat 10.78% | $3.7B |
| Aug 8, 2024 | $0.68 | $0.69 | Beat 1.77% | $3.8B |
| May 9, 2024 | $0.67 | $0.67 | Miss -0.45% | $3.7B |
| Feb 28, 2024 | $0.67 | $0.61 | Miss -8.96% | $3.8B |
| Feb 27, 2023 | $0.72 | $0.67 | Miss -6.94% | $3.9B |
Reported results against consensus at the time of each report · Surprise is computed from the estimate on record · Data as of Nov 5, 2026